[go: up one dir, main page]

SG11201603063WA - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents

Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Info

Publication number
SG11201603063WA
SG11201603063WA SG11201603063WA SG11201603063WA SG11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA SG 11201603063W A SG11201603063W A SG 11201603063WA
Authority
SG
Singapore
Prior art keywords
pain
prevention
compounds
treatment
neurodegenerative diseases
Prior art date
Application number
SG11201603063WA
Other languages
English (en)
Inventor
Jim-Min Fang
Yun-Lian Lin
Jung-Hsin Lin
Chun-Jung Lin
Yijuang Chern
Nai-Kuei Huang
Hung-Li Wang
Benjamin Pang-Hsien Tu
Chih-Cheng Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of SG11201603063WA publication Critical patent/SG11201603063WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/167Purine radicals with ribosyl as the saccharide radical
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11201603063WA 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain SG11201603063WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (1)

Publication Number Publication Date
SG11201603063WA true SG11201603063WA (en) 2016-05-30

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603063WA SG11201603063WA (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Country Status (14)

Country Link
US (1) US10301348B2 (es)
EP (1) EP3060566B1 (es)
JP (1) JP6534997B2 (es)
KR (1) KR102313314B1 (es)
CN (1) CN106414456B (es)
AU (1) AU2014340114B2 (es)
BR (1) BR112016008901B1 (es)
CA (1) CA2927699C (es)
IL (1) IL245103B (es)
MX (1) MX367707B (es)
RU (1) RU2695358C2 (es)
SG (1) SG11201603063WA (es)
WO (1) WO2015061426A1 (es)
ZA (1) ZA201603118B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614686A (zh) 2015-05-29 2018-01-19 小利兰·斯坦福大学托管委员会 用于降低含有延伸的核苷酸重复序列的基因的有害活性的核苷试剂
WO2018140734A1 (en) 2017-01-27 2018-08-02 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
WO2023154804A2 (en) * 2022-02-10 2023-08-17 Academica Sinica Method of treating spinal cord injury and composition for use therein
TW202416962A (zh) * 2022-07-07 2024-05-01 中央研究院 治療思覺失調症之方法及用於其中之組成物
TW202435868A (zh) * 2022-12-29 2024-09-16 中央研究院 治療睡眠障礙之方法及用於其中之組成物
WO2024196760A1 (en) * 2023-03-17 2024-09-26 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
EP0550631B1 (en) * 1990-09-25 1997-01-02 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
KR101830623B1 (ko) * 2009-11-13 2018-02-21 아카데미아 시니카 신경퇴화 질병의 예방 및 치료를 위해 아데노신 a2a 수용기 및 아데노신 수송체를 표적화하는 이중-작용 화합물
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
JP6208693B2 (ja) * 2012-02-09 2017-10-04 ブランドバンプス,エルエルシー 改良されたグリップを有する装飾された検知可能な警告パネル
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Also Published As

Publication number Publication date
AU2014340114B2 (en) 2018-10-18
MX367707B (es) 2019-09-03
KR20160086852A (ko) 2016-07-20
CA2927699C (en) 2022-07-05
RU2695358C2 (ru) 2019-07-23
JP2016535019A (ja) 2016-11-10
MX2016005174A (es) 2016-08-11
IL245103A0 (en) 2016-06-30
NZ719740A (en) 2021-02-26
CN106414456A (zh) 2017-02-15
IL245103B (en) 2019-02-28
CN106414456B (zh) 2018-12-14
EP3060566B1 (en) 2018-09-05
EP3060566A4 (en) 2017-06-14
BR112016008901B1 (pt) 2022-08-23
ZA201603118B (en) 2019-04-24
WO2015061426A1 (en) 2015-04-30
US20160264613A1 (en) 2016-09-15
CA2927699A1 (en) 2015-04-30
KR102313314B1 (ko) 2021-10-19
BR112016008901A2 (pt) 2020-05-12
RU2016118282A3 (es) 2018-06-18
RU2016118282A (ru) 2017-11-28
JP6534997B2 (ja) 2019-06-26
US10301348B2 (en) 2019-05-28
EP3060566A1 (en) 2016-08-31
AU2014340114A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
HK1222530A1 (zh) 用於皮膚處理的微閉合及相關方法
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
PL3031826T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
EP2836270A4 (en) SYSTEMS AND METHODS RELATED TO THE TREATMENT OF BACK PAIN
EP2943189A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEMYELINATING DISEASES
ZA201603118B (en) Compounds for use in prevention and treatment of neurodegenerative diseases and pain
HK1220352A1 (zh) 和神經變性疾病的治療
GB201311361D0 (en) Compounds and their therapeutic use
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
SI3598971T1 (sl) Odmerne oblike in terapevtske uporabe L-4-klorokinurenina
HK1222585A1 (zh) 用於提供疼痛減輕和麻醉的二氫埃托啡
IL246036B (en) A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
EP2964227A4 (en) TREATMENT AND PROPHYLAXIS OF RENAL DISEASES
EP2986294A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
GB201308736D0 (en) Compounds and their therapeutic use
HK1218882A1 (zh) 用於治療神經退化疾病和其它疾病的組合治療劑和方法
ZA201506396B (en) Use of sedoheptulose for prevention or treatment of inflammation
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
EP2986295A4 (en) COMPOUNDS FOR THE TREATMENT OF PAIN
HUP1300454A2 (hu) Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására
GB201317373D0 (en) Treatment and prevention of cancer
GB201309001D0 (en) Methods for prevention and treatment of preeclampsia
GB201317804D0 (en) Therapeutic compounds and their use